ALBENDAZOLE

Post-LOESM

albendazole

ANDAORALTABLET
Approved
Jan 2021
Lifecycle
Post-LOE
Competitive Pressure
30/100
Clinical Trials
5

Mechanism of Action

Cytochrome P450 1A Inducers

Pharmacologic Class:

Anthelmintic

Clinical Trials (5)

NCT07258173Phase 2Not Yet Recruiting

Efficacy and Safety of a Single Dose of Emodepside Compared to a Single Dose of Albendazole in Adolescents and Adults Infected With Trichuris Incognita

Started Jan 2026
100 enrolled
Trichuris InfectionTrichuris
NCT06201559Phase 1Completed

Bioequivalence Study Between Two Albendazole 400 mg Tablets in Healthy Adult Participants Under Fed Conditions

Started Aug 2023
70 enrolled
Intestinal Diseases
NCT04913610Phase 2Terminated

Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection

Started May 2021
153 enrolled
Onchocerciasis
NCT01755637Phase 1Completed

Bioequivalence Study of Albendazole 400 mg Tablets in Chinese Population

Started Apr 2012
56 enrolled
Helminthiasis
NCT00659997Phase 4Completed

Efficacy Albendazole and Levamisole Against STH on Unguja

Started Jun 2006
20 enrolled
AscariasisTrichuriasis